OTCPK:CCEL

Stock Analysis Report

Cryo-Cell International

Executive Summary

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use.

Snowflake

Fundamentals

Overvalued with poor track record.


Similar Companies

Share Price & News

How has Cryo-Cell International's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.1%

CCEL

5.8%

US Healthcare

1.8%

US Market


1 Year Return

17.9%

CCEL

-6.5%

US Healthcare

7.3%

US Market

Return vs Industry: CCEL exceeded the US Healthcare industry which returned -6.5% over the past year.

Return vs Market: CCEL exceeded the US Market which returned 7.3% over the past year.


Shareholder returns

CCELIndustryMarket
7 Day2.1%5.8%1.8%
30 Day11.6%2.5%-0.7%
90 Day6.3%-1.8%0.06%
1 Year17.9%17.9%-5.0%-6.5%9.7%7.3%
3 Year106.7%106.7%33.9%28.6%46.3%36.9%
5 Year191.0%191.0%65.6%55.8%64.5%46.5%

Price Volatility Vs. Market

How volatile is Cryo-Cell International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cryo-Cell International undervalued compared to its fair value and its price relative to the market?

39.2%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: CCEL ($8.48) is trading below our estimate of fair value ($13.95)

Significantly Undervalued: CCEL is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: CCEL is poor value based on its PE Ratio (45x) compared to the Healthcare industry average (20.4x).

PE vs Market: CCEL is poor value based on its PE Ratio (45x) compared to the US market (17.7x).


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate CCEL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CCEL has negative assets, so we can't compare its PB Ratio to the US Healthcare industry average.


Next Steps

Future Growth

How is Cryo-Cell International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

10.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cryo-Cell International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of CCEL’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Cryo-Cell International's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Cryo-Cell International performed over the past 5 years?

-22.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CCEL's earnings have declined by -22.8% per year over the past 5 years.

Accelerating Growth: CCEL has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: CCEL has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (5.3%).


Return on Equity

High ROE: CCEL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: CCEL has a higher Return on Assets than the Healthcare industry average last year.


Return on Capital Employed

ROCE Improving: CCEL's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Cryo-Cell International's financial position?


Financial Position Analysis

Short Term Liabilities: CCEL has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: CCEL has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: CCEL has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: CCEL's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Debt Coverage: CCEL's debt is well covered by operating cash flow (52%).

Interest Coverage: CCEL's interest payments on its debt are not well covered by EBIT (2.2x coverage).


Balance Sheet

Inventory Level: CCEL has a low level of unsold assets or inventory.

Debt Coverage by Assets: CCEL has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Next Steps

Dividend

What is Cryo-Cell International's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage1.6%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate CCEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CCEL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CCEL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CCEL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CCEL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Cryo-Cell International's salary, the management and board of directors tenure and is there insider trading?

8.2yrs

Average management tenure


CEO

David Portnoy (56yo)

8.2yrs

Tenure

US$981,576

Compensation

Mr. David I. Portnoy has been Co-Chief Executive Officer of Cryo-Cell International, Inc. since August 31, 2011. Mr. Portnoy serves as the President of Focus Financial Corp., a private investment banking a ...


CEO Compensation Analysis

Compensation vs. Market: David's total compensation ($USD981.58K) is about average for companies of similar size in the US market ($USD491.38K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.


Management Age and Tenure

8.2yrs

Average Tenure

52yo

Average Age

Experienced Management: CCEL's management team is seasoned and experienced (8.2 years average tenure).


Board Age and Tenure

8.2yrs

Average Tenure

55yo

Average Age

Experienced Board: CCEL's board of directors are considered experienced (8.2 years average tenure).


Insider Trading

Insider Buying: CCEL insiders have bought and sold the same number of shares in the past 3 months.


Recent Insider Transactions

SellUS$150,80020 Sep 19
Mark Portnoy
EntityIndividual
Role
Member of the Board of Directors
Co-CEO & Director
Shares20,000
Max PriceUS$7.54
BuyUS$150,80020 Sep 19
Mark Portnoy
EntityIndividual
Role
Member of the Board of Directors
Co-CEO & Director
Shares20,000
Max PriceUS$7.54
BuyUS$70,00002 May 19
Jonathan Wheeler
EntityIndividual
Role
Member of Advisory Board
Director & Member of Advisory Board
Shares10,000
Max PriceUS$7.00
BuyUS$26,58624 Apr 19
Arthur Ellis
EntityIndividual
Role
Member of the Board of Directors
Director
Shares3,853
Max PriceUS$6.90
BuyUS$76,75511 Feb 19
Iszo Capital Management LP
EntityCompany
Shares10,750
Max PriceUS$7.14
BuyUS$25,64204 Feb 19
David Portnoy
EntityIndividual
Role
Co-Chief Executive Officer
Chairman & Co-CEO
Shares3,800
Max PriceUS$6.75
BuyUS$14,70011 Jan 19
Iszo Capital Management LP
EntityCompany
Shares2,100
Max PriceUS$7.00
BuyUS$15,96013 Nov 18
Iszo Capital Management LP
EntityCompany
Shares2,280
Max PriceUS$7.00
BuyUS$34,00023 Oct 18
Arthur Ellis
EntityIndividual
Role
Member of the Board of Directors
Director
Shares5,000
Max PriceUS$6.80

Ownership Breakdown


Management Team

  • Jill Taymans (49yo)

    CFO & VP of Finance

    • Tenure: 21.4yrs
    • Compensation: US$198.70k
  • Merri Mair

    Medical Director & Member of Medical & Scientific Team

    • Tenure: 0yrs
  • Mark Portnoy (55yo)

    Co-CEO & Director

    • Tenure: 8.2yrs
    • Compensation: US$756.65k
  • David Portnoy (56yo)

    Chairman & Co-CEO

    • Tenure: 8.2yrs
    • Compensation: US$981.58k
  • Oleg Mikulinsky (46yo)

    Chief Information Officer

    • Tenure: 7.6yrs
    • Compensation: US$337.58k

Board Members

  • George Gaines (65yo)

    Director

    • Tenure: 8.2yrs
    • Compensation: US$40.36k
  • Merri Mair

    Medical Director & Member of Medical & Scientific Team

    • Tenure: 0yrs
  • Mark Portnoy (55yo)

    Co-CEO & Director

    • Tenure: 8.2yrs
    • Compensation: US$756.65k
  • Harold Berger (55yo)

    Director

    • Tenure: 8.2yrs
    • Compensation: US$39.86k
  • David Portnoy (56yo)

    Chairman & Co-CEO

    • Tenure: 8.2yrs
    • Compensation: US$981.58k
  • Jonathan Wheeler (59yo)

    Director & Member of Advisory Board

    • Tenure: 0yrs
    • Compensation: US$40.36k
  • Brian Sheehy (48yo)

    Director

    • Tenure: 1.2yrs
    • Compensation: US$9.88k
  • Arthur Ellis (54yo)

    Director

    • Tenure: 1.2yrs
    • Compensation: US$10.88k

Company Information

Cryo-Cell International, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cryo-Cell International, Inc.
  • Ticker: CCEL
  • Exchange: OTCPK
  • Founded: 1989
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$66.133m
  • Shares outstanding: 7.80m
  • Website: https://www.cryo-cell.com

Number of Employees


Location

  • Cryo-Cell International, Inc.
  • 700 Brooker Creek Boulevard
  • Suite 1800
  • Oldsmar
  • Florida
  • 34677
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CCELOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJan 1991

Biography

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provide ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 23:35
End of Day Share Price2019/10/17 00:00
Earnings2019/05/31
Annual Earnings2018/11/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.